CUE BIOPHARMA INC (CUE)

US22978P1066 - Common Stock

1.84  0 (0%)

Premarket: 1.82 -0.02 (-1.09%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CUE BIOPHARMA INC

NASDAQ:CUE (3/27/2024, 8:07:24 PM)

Premarket: 1.82 -0.02 (-1.09%)

1.84

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap83.02M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CUE Daily chart

Company Profile

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Boston, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-01-02. The firm is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patient’s intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Company’s lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilms’ Tumor 1 protein (WT-1), an oncofetal antigen. The company is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.

Company Info

CUE BIOPHARMA INC

40 Guest Street

Boston MASSACHUSETTS 02139

P: 16179492680

CEO: Daniel R. Passeri

Employees: 51

Website: https://www.cuebiopharma.com/

CUE News

News Image15 days ago - ChartmillWednesday's session: gap up and gap down stocks

These stocks are gapping in today's session

News Imagea month ago - Cue Biopharma, Inc.Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
News Imagea month ago - Cue Biopharma, Inc.Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image2 months ago - Cue Biopharma, Inc.Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
News Image4 months ago - InvestorPlaceCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.

News Image4 months ago - BusinessInsiderCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ:CUE) just reported results for the third quarter of 2023....

CUE Twits

Here you can normally see the latest stock twits on CUE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example